An engineered virus kills cancer cells more effectively than another virus currently used in treatments, according to Hokkaido University researchers.
Hokkaido University researchers have engineered a virus that selectively targets and kills cancer cells. The virus, called dl355, has an even stronger anticancer effect than another engineered virus currently used in clinical practice, according to a study published in the journal Oncology Reports.
Molecular oncologist Fumihiro Higashino and colleagues deleted a gene involved in viral replication, called E4orf6, from a type of adenovirus. The team previously discovered that E4orf6 stabilizes a type of mRNA called ARE-mRNAs in the infected cells enabling viral replication. ARE-mRNAs are known to be stable in stressed cells and cancer cells, but rapidly degrade in normal cells.
In laboratory tests, they found that their modified adenovirus, called dl355, replicated and increased its number significantly more in cancer cells than it did in normal cells. Higashino explains “The E4orf6-lacking virus relies on the stable ARE-mRNAs in cancer cells for its replication.”
Some viruses can be used to treat cancers, as they replicate within the cells until they burst and die. The researchers infected several types of cultured cancer cells with 100 dl355 virus particles per cell and found that nearly all the cancer cells died within seven days. In contrast, most normal cells infected with the virus did not die, even after seven days. Several cancer cell lines managed to survive low doses of dl355, but all cancer cells were killed by the virus as the dose was increased. Tumour growth was also significantly suppressed when dl355 was administered to human tumour cells grown in mice.
Finally, the team compared the anticancer effects of dl355 with another anticancer adenovirus currently used in clinical practice, called dl1520. dl355 replication was higher in all cancer cell lines tested, including cervical and lung cancer cells, and was better at killing all but one type of cancer cell, compared to dl1520. Both viruses only killed very few normal cells.
The findings suggest that dl355 has potential to be an effective anticancer treatment, the team concludes. They suggest enhancing the stabilization of ARE-mRNAs in cancer cells could even further strengthen its effect, but Professor Higashino notes that further research is required. “While we think dl355 has the potential to be an effective treatment method in dealing with many types of cancers, much more research needs to be done. When we think of a timeline, at least five more years of further research may be required, possible more, on top of clinical trials,” Professor Higashino noted.
Learn more: Engineering a cancer-fighting virus
The Latest on: Engineered virus
via Google News
The Latest on: Engineered virus
- FDA's Efforts to Advance the Development of Biologics on April 17, 2019 at 7:40 am
The modified cells are then infused back into the patient ... CBER approved HEPLISAV-B, a Hepatitis B vaccine to prevent infection caused by all known subtypes of hepatitis B virus in adults 18 of age ... […]
- Safe and Effective Vaccine Developed Against Nipah Virus on April 15, 2019 at 2:29 am
The new vaccine in live and inactivated forms was developed to protect from this deadly virus using modified rabies virus vector.’ Currently, there is no approved vaccine against Nipah virus available ... […]
- Developing a vaccine against Nipah virus on April 15, 2019 at 2:02 am
Dr. Schnell, together with the first author and graduate student Rohan Keshwara, took advantage of a modified rabies virus vector, and incorporated a gene from Nipah virus—creating a viral ... […]
- Scientists develop a vaccine to protect against the deadly Nipah virus on April 14, 2019 at 11:28 pm
Scientists at Jefferson modified an existing rabies vaccine to create the jab, because the viruses are physically similar, they said. It works by training the body to prevent the virus causing disease ... […]
- Oncolytic Virus Therapy Market to grow at a CAGR of 19.32% in the forecast period 2019-26 as the world is introduced to a safer way to fight cancer on April 12, 2019 at 9:56 am
An oncolytic virus is a genetically engineered or naturally occurring virus that can imitate in selected terms and kill cancer cells without harming the normal tissues. Oncolytic Virus therapy is a ... […]
- How much do you know about genetically modified food and non-GMO labels? on April 11, 2019 at 3:01 am
“That’s been very, very effective, and today, something like 90 per cent of Hawaiian papaya is genetically engineered and resistant to the virus,” Ronald says, comparing the concept to ... […]
- New HIV vaccine could expose latent virus and kill it on April 9, 2019 at 11:29 pm
"In some people, 1 one out of every 5 T cells are specific to that one virus," adds Rinaldo. "That got us thinking — maybe those cells that are specific to fighting CMV also make up a large part of ... […]
- Cytonus Therapeutics Cargocyte Platform for Delivery of Oncolytic Viruses to be Highlighted at the ASGCT Annual Meeting on April 9, 2019 at 7:11 am
Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune ... […]
- First-of-Its-Kind HIV Therapy Draws out the Virus, Then Kills It on April 6, 2019 at 5:07 pm
In a study published Tuesday in the journal EBioMedicine, the Pitt team details how it engineered an immunotherapy called MDC1 to target both HIV and Cytomegalovirus (CMV), a virus that infects ... […]
- New HIV therapy ‘kicks’ virus out of hiding and ‘kills’ it on April 5, 2019 at 5:45 pm
As researchers expected, HIV was indeed lying dormant in the CMV-infected cells, with the engineered MDC1 cells reactivating the latent virus. But beyond just detecting the virus, the engineered MDC1 ... […]
via Bing News